A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy.
diffuse proliferative glomerulonephritis
procainamide
clinical lupus syndrome
procainamide
lupus erythematosus
procainamide